{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:25:09Z","timestamp":1770423909741,"version":"3.49.0"},"reference-count":69,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,5]]},"abstract":"<jats:title>PLAIN ENGLISH SUMMARY<\/jats:title>\n               <jats:sec>\n                  <jats:title>\u2009<\/jats:title>\n                  <jats:p>In the last 5\u201310 years, several large high-quality research trials testing new treatments versus a dummy treatment in patients with kidney disease have provided new discoveries, particularly among people with diabetes. Some of these trials included patients with a wide variety of kidney diseases and therefore provided important information on how effective the treatment is, and whether it is safe to use for many people (and not just those with a specific type of kidney disease). The findings are particularly important as they suggest that, once established, kidney disease progresses in similar ways regardless of the initiating cause. These new treatments importantly slow kidney disease progression but, even when used together, do not arrest the loss of kidney function. New research is still needed to test new potential treatments.<\/jats:p>\n                  <jats:p>\u2003Now that we have several drugs that can be used to treat kidney disease, there are new challenges when designing and conducting new trials. These include the reduced risk of kidney disease progression and heart disease (because of the new treatments available). Future research trials need to include a sufficiently large number of patients to be able to answer research questions reliably. In addition, different types of people and diseases should be included. In an age of increasing regulation and bureaucracy, conducting such trials is challenging. Simplifying the design and conduct of future trials by focusing only on the necessary components needed to answer the research key question(s) is important. Such trials reduce the burden of participation for patients and busy clinical staff, whilst still ensuring careful focus on patient safety and data quality. We hope more high-quality trials that are sufficiently large, inclusive and simple will be conducted in the future, so that kidney teams can offer better care to their patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Nephrology has benefited from conducting increasingly large high-quality trials in the last 5\u201310 years. In addition to the long-standing known benefits of renin\u2013angiotensin system inhibitors, we now have multiple pharmacotherapies that provide kidney and\/or cardiovascular protection for certain types of patient with chronic kidney disease (CKD). These include sodium-glucose co-transporter 2 inhibitors (SGLT2i), a non-steroidal mineralocorticoid receptor antagonist and a glucagon-like peptide-1 receptor agonist. Trials of SGLT2i have had particularly important impact, as wide eligibility criteria in pivotal trials have enabled safety and efficacy across a wide range of causes of CKD to be demonstrated. These findings support the concept of final common pathways of CKD progression and should encourage similar trial designs recruiting broad ranges of patients at risk of CKD progression. This is important as these new drugs do not completely arrest CKD progression nor do they mitigate the full excess of cardiovascular disease.<\/jats:p>\n                  <jats:p>\u2003In the current era of multiple therapies to manage risk of CKD progression, trial design and conduct also need to consider new challenges. These include falling event rates, establishing standard of care for participants pre-randomization and improving the inclusion of trial participants understudied in previous trials. Streamlining trial design and conduct and reducing participation burden for patients and clinicians is increasingly important to facilitate larger sample sizes and to optimize adherence to study interventions and follow-up. Potential other solutions include maintaining a focus on wide generalizability (to include understudied patient groups) and empowering patients to volunteer for trials (through public and patient involvement and large-scale invitation methods), as well as innovations in trial design (including use of pre-randomization run-in periods to implement standard of care and factorial or platform trials to assess multiple treatments simultaneously).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfae210","type":"journal-article","created":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T03:21:51Z","timestamp":1726888911000},"page":"i70-i79","source":"Crossref","is-referenced-by-count":6,"title":["Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease"],"prefix":"10.1093","volume":"40","author":[{"given":"Doreen","family":"Zhu","sequence":"first","affiliation":[{"name":"Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford , Oxford ,","place":["UK"]},{"name":"Oxford Kidney Unit, Oxford University Hospitals NHS Foundation Trust , Oxford ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parminder K","family":"Judge","sequence":"additional","affiliation":[{"name":"Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford , Oxford ,","place":["UK"]},{"name":"Oxford Kidney Unit, Oxford University Hospitals NHS Foundation Trust , Oxford ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Staplin","sequence":"additional","affiliation":[{"name":"Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford , Oxford ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1179-0023","authenticated-orcid":false,"given":"Richard","family":"Haynes","sequence":"additional","affiliation":[{"name":"Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford , Oxford ,","place":["UK"]},{"name":"Oxford Kidney Unit, Oxford University Hospitals NHS Foundation Trust , Oxford ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1172-8243","authenticated-orcid":false,"given":"William G","family":"Herrington","sequence":"additional","affiliation":[{"name":"Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford , Oxford ,","place":["UK"]},{"name":"Oxford Kidney Unit, Oxford University Hospitals NHS Foundation Trust , Oxford ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"2025020513211395200_bib1","first-page":"\u2013","article-title":"Global, regional, and national burden of chronic kidney disease, 1990","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","journal-title":"Lancet North Am Ed"},{"key":"2025020513211395200_bib2","first-page":"100625","article-title":"Reducing the gap of chronic kidney disease in low- and middle-income countries: what is missing?","volume":"28","author":"Lopez","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"2025020513211395200_bib3","doi-asserted-by":"publisher","first-page":"\u2013","DOI":"10.1371\/journal.pone.0264393","article-title":"Prevalence of chronic kidney disease stages 3","volume":"17","author":"Suriyong","year":"2022","journal-title":"PLoS One"},{"key":"2025020513211395200_bib4","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"2025020513211395200_bib5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.kint.2017.04.019","article-title":"Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference","volume":"92","author":"Baigent","year":"2017","journal-title":"Kidney Int"},{"key":"2025020513211395200_bib6","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/S0140-6736(17)30788-2","article-title":"Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy","volume":"390","author":"Levin","year":"2017","journal-title":"Lancet North Am Ed"},{"key":"2025020513211395200_bib7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/01.ASN.0000100125.21491.46","article-title":"The number, quality, and coverage of randomized controlled trials in nephrology","volume":"15","author":"Strippoli","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2025020513211395200_bib8","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2025020513211395200_bib9","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2025020513211395200_bib10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"2025020513211395200_bib11","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2025020513211395200_bib12","first-page":"1788","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium","year":"2022","journal-title":"Lancet North Am Ed"},{"key":"2025020513211395200_bib13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(23)00322-4","article-title":"Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial","volume":"12","author":"The EMPA-KIDNEY Collaborative Group","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025020513211395200_bib14","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"2025020513211395200_bib15","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2025020513211395200_bib16","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2025020513211395200_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.kisu.2021.11.008","article-title":"Considerations for the future: current and future treatment paradigms with mineralocorticoid receptor antagonists-unmet needs and underserved patient cohorts","volume":"12","author":"Epstein","year":"2022","journal-title":"Kidney Int Suppl"},{"key":"2025020513211395200_bib18","article-title":"A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression","year":"2024"},{"key":"2025020513211395200_bib19","article-title":"Studies of Heart Kidney Protection with BI 690517 in Combination With Empagliflozin: A Multicenter, International, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Aldosterone Synthase Inhibitor BI 690517 in combination With Empagliflozin in Patients With Chronic Kidney Disease 2024"},{"key":"2025020513211395200_bib20","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025020513211395200_bib21","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1093\/ndt\/gfad009","article-title":"The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease","volume":"38","author":"Rossing","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2025020513211395200_bib22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2025020513211395200_bib23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(00)03651-5","article-title":"Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials","volume":"357","author":"Collins","year":"2001","journal-title":"Lancet North Am Ed"},{"key":"2025020513211395200_bib24","first-page":"161","article-title":"Clinical trials: why and how in nephrology","volume-title":"Oxford Textbook of Clinical Nephrology: Three-Volume Pack","author":"Haynes","year":"2015"},{"key":"2025020513211395200_bib25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta7270","article-title":"Evaluating non-randomised intervention studies","volume":"7","author":"Deeks","year":"2003","journal-title":"Health Technol Assess"},{"key":"2025020513211395200_bib26","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41581-019-0212-x","article-title":"Kidney disease trials for the 21st century: innovations in design and conduct","volume":"16","author":"Herrington","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"2025020513211395200_bib27","article-title":"Guidance for Good Randomized Clinical Trials","author":"Good Clinical Trials Collaborative","year":"2022"},{"key":"2025020513211395200_bib28","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"The RECOVERY Collaborative Group","year":"2021","journal-title":"N Engl J Med"},{"key":"2025020513211395200_bib29","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1002\/sim.4780101010","article-title":"Estimating the effect of the run-in on the power of the Physicians\u2019 Health Study","volume":"10","author":"Lang","year":"1991","journal-title":"Stat Med"},{"key":"2025020513211395200_bib30","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Drueke","year":"2006","journal-title":"N Engl J Med"},{"key":"2025020513211395200_bib31","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"2025020513211395200_bib32","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"AIM-HIGH Investigators","year":"2011","journal-title":"N Engl J Med"},{"key":"2025020513211395200_bib33","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"HPS2-THRIVE Collaborative Group","year":"2014","journal-title":"N Engl J Med"},{"key":"2025020513211395200_bib34","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1681\/ASN.2017101062","article-title":"Should we increase GFR with bardoxolone in Alport Syndrome?","volume":"29","author":"Baigent","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2025020513211395200_bib35","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s00125-019-05049-8","article-title":"Streamlined mail-based methods for large randomised trials: lessons learnt from the ASCEND study","volume":"63","author":"Mafham","year":"2020","journal-title":"Diabetologia"},{"key":"2025020513211395200_bib36","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s13063-016-1354-9","article-title":"Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events iN Diabetes (ASCEND)","volume":"17","author":"Aung","year":"2016","journal-title":"Trials"},{"key":"2025020513211395200_bib37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/2047-1440-2-7","article-title":"Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol","volume":"2","author":"Haynes","year":"2013","journal-title":"Transplant Res"},{"key":"2025020513211395200_bib38","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1111\/ajt.14619","article-title":"Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study)\u2014results of a randomized controlled clinical trial","volume":"18","author":"The 3C Study Collaborative Group","year":"2018","journal-title":"Am J Transplant"},{"key":"2025020513211395200_bib39","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1093\/ndt\/gfac040","article-title":"Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial","volume":"37","author":"The EMPA-KIDNEY Collaborative Group","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 1","key":"2025020513211395200_bib40","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1097\/QAI.0000000000000033","article-title":"Addressing standards of care in resource-limited settings","volume":"65","author":"Dawson","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025020513211395200_bib41","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1093\/ckj\/sfac029","article-title":"Sodium-glucose cotransporter inhibition in polycystic kidney disease: fact or fiction","volume":"15","author":"Afsar","year":"2022","journal-title":"Clin Kidney J"},{"key":"2025020513211395200_bib42","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"HPS3\/TIMI55-REVEAL Collaborative Group","year":"2017","journal-title":"N Engl J Med"},{"key":"2025020513211395200_bib43","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group","volume":"334","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"key":"2025020513211395200_bib44","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet North Am Ed"},{"key":"2025020513211395200_bib45","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1186\/s13063-021-05849-7","article-title":"Promoting inclusion in clinical trials-a rapid review of the literature and recommendations for action","volume":"22","author":"Bodicoat","year":"2021","journal-title":"Trials"},{"key":"2025020513211395200_bib46","article-title":"Improving inclusion","author":"NIHR","year":"2020"},{"key":"2025020513211395200_bib47","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1053\/j.ajkd.2017.12.018","article-title":"Establishing a core outcome measure for fatigue in patients on hemodialysis: a Standardized Outcomes in Nephrology-Hemodialysis (SONG-HD) Consensus Workshop Report","volume":"72","author":"Ju","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"2025020513211395200_bib48","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1681\/ASN.2019010008","article-title":"Evaluating glomerular filtration rate slope as a surrogate end point for ESKD in clinical trials: an individual participant meta-analysis of observational data","volume":"30","author":"Grams","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2025020513211395200_bib49","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S2213-8587(23)00321-2","article-title":"Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial","volume":"12","author":"The EMPA-KIDNEY Collaborative Group","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025020513211395200_bib50","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet North Am Ed"},{"key":"2025020513211395200_bib51","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1136\/bmj.316.7141.1337","article-title":"ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group","volume":"316","author":"Baigent","year":"1998","journal-title":"BMJ"},{"key":"2025020513211395200_bib52","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1742-1241.2002.tb11192.x","article-title":"The MRC\/BHF Heart Protection Study: preliminary results","volume":"56","author":"Collins","year":"2002","journal-title":"Int J Clin Pract"},{"key":"2025020513211395200_bib53","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ahj.2007.06.034","article-title":"Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors","volume":"154","author":"SEARCH Study Collaborative Group","year":"2007","journal-title":"Am Heart J"},{"key":"2025020513211395200_bib54","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"ASCEND Study Collaborative Group","year":"2018","journal-title":"N Engl J Med"},{"key":"2025020513211395200_bib55","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1186\/s13063-022-06680-4","article-title":"Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units","volume":"23","author":"Love","year":"2022","journal-title":"Trials"},{"key":"2025020513211395200_bib56","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1053\/j.ajkd.2022.01.430","article-title":"Platform clinical trials within nephrology-interpreting the evidence","volume":"80","author":"Kotwal","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"2025020513211395200_bib57","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa010877","article-title":"Daily hemodialysis and the outcome of acute renal failure","volume":"346","author":"Schiffl","year":"2002","journal-title":"N Engl J Med"},{"key":"2025020513211395200_bib58","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1056\/NEJMoa0802639","article-title":"Intensity of renal support in critically ill patients with acute kidney injury","volume":"359","author":"The VA\/NIH Acute Renal Failure Trial Network","year":"2008","journal-title":"N Engl J Med"},{"key":"2025020513211395200_bib59","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa0902413","article-title":"Intensity of continuous renal-replacement therapy in critically ill patients","volume":"361","author":"The RENAL Replacement Therapy Study Investigators","year":"2009","journal-title":"N Engl J Med"},{"key":"2025020513211395200_bib60","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N Engl J Med"},{"key":"2025020513211395200_bib61","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(10)62039-9","article-title":"Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial","volume":"376","author":"Symplicity HTN-2 Investigators","year":"2010","journal-title":"Lancet"},{"key":"2025020513211395200_bib62","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","article-title":"A controlled trial of renal denervation for resistant hypertension","volume":"370","author":"Bhatt","year":"2014","journal-title":"N Engl J Med"},{"key":"2025020513211395200_bib63","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","journal-title":"Lancet"},{"key":"2025020513211395200_bib64","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jvs.2006.12.054","article-title":"Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions","volume":"45","author":"Heart Protection Study Collaborative Group","year":"2007","journal-title":"J Vasc Surg"},{"key":"2025020513211395200_bib65","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"EVOLVE Trial Investigators","year":"2012","journal-title":"N Engl J Med"},{"key":"2025020513211395200_bib66","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2215\/CJN.06370615","article-title":"Lessons learned from EVOLVE for planning of future randomized trials in patients on dialysis","volume":"11","author":"Parfrey","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025020513211395200_bib67","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1464-5491.2007.02097.x","article-title":"Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis","volume":"24","author":"Jennings","year":"2007","journal-title":"Diabet Med"},{"key":"2025020513211395200_bib68","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"2025020513211395200_bib69","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJM198010303031804","article-title":"Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project","volume":"303","author":"Coronary Drug Project Research Group","year":"1980","journal-title":"N Engl J Med"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/Supplement_1\/i70\/61766404\/gfae210.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/Supplement_1\/i70\/61766404\/gfae210.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T13:23:43Z","timestamp":1738761823000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/40\/Supplement_1\/i70\/8002190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":69,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2025,2,5]]},"published-print":{"date-parts":[[2025,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfae210","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2025,1]]}}}